Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule

INTRODUCTION: Regorafenib is a tyrosine kinase inhibitor (TKI) approved in metastatic gastrointestinal stromal tumor (GIST), colorectal cancer, and hepatocarcinoma. Anyway, the toxicity profile of Regorafenib standard schedule is associated with poor compliance and a high rate of discontinuation. Fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimaudo, Maria Susanna, Laffi, Alice, Gennaro, Nicolò, Fazio, Roberta, D’Orazio, Federico, Samà, Laura, Siracusano, Licia Vanessa, Sicoli, Federico, Renne, Salvatore Lorenzo, Santoro, Armando, Bertuzzi, Alexia Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264664/
https://www.ncbi.nlm.nih.gov/pubmed/37324004
http://dx.doi.org/10.3389/fonc.2023.1190123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264664/
https://www.ncbi.nlm.nih.gov/pubmed/37324004
http://dx.doi.org/10.3389/fonc.2023.1190123

Ejemplares similares